The right candidate for ChondroFiller injection

Is your cartilage damage the right kind for ChondroFiller injection? That question sits at the heart of most consultations, and the answer depends on two straightforward filters: the location and extent of the damage.

ChondroFiller injection is designed for an isolated, focal cartilage defect — a localised area of damage with healthy cartilage around it, graded ICRS (International Cartilage Repair Society) Grade III or IV. Grade III means the damage extends more than halfway through the cartilage layer; Grade IV means it reaches the underlying bone. The defect should have intact surrounding borders, because those healthy edges help anchor the injectable scaffold in place.

In terms of size, the treatment is indicated for defects up to 6 cm² — a broader ceiling than the 2–4 cm² range historically associated with microfracture, making it relevant to the mid-to-large focal lesion that can sit between smaller defects and those requiring major reconstructive surgery.

What ChondroFiller is not is a painkiller or a lubricant. Unlike a steroid or hyaluronic acid injection, it is a CE-marked Class III acellular collagen scaffold that supports the body's own repair process — resident progenitor cells migrate into the gelled scaffold and produce new cartilage-like tissue over time.

Patients who are unsuitable for, or prefer to avoid, arthroscopic surgery may also be candidates, since ChondroFiller injection is delivered as an outpatient procedure under local anaesthesia with ultrasound guidance — no operating theatre required.

How the collagen scaffold triggers cartilage repair

Think of the scaffold as temporary scaffolding inside a damaged building: it holds the space open, gives workers a structure to build on, and is gradually removed once the new material is strong enough to stand alone. ChondroFiller injection works on exactly that principle.

The product is a liquid form of Type I collagen — the same protein found in healthy cartilage — derived from murine (mouse) sources. Injected under ultrasound guidance, it self-gels within minutes on contact with body temperature inside the defect, conforming to the shape of the lesion without requiring a dry surgical field.

Critically, the scaffold contains no donor cells. Instead, it acts as a chemical and structural signal that draws the patient's own progenitor cells — already present in surrounding tissue and joint fluid — into the defect. Once inside, those cells differentiate into chondrocytes (the specialised cartilage-producing cells) and begin laying down hyaline-like repair tissue. As that tissue matures, the collagen scaffold degrades and is replaced by the body's own matrix. This process is called matrix-induced chondrogenesis.

The distinction from other joint injections matters here. Hyaluronic acid adds lubrication but does not form a scaffold; the effect is temporary. Steroid injections reduce inflammation without restoring tissue. Microfracture drills into bone to trigger a bleeding response, but the resulting fibrocartilage is structurally weaker and may deteriorate within two to three years.

Post-treatment MRI scans in treated patients have shown measurable structural changes — including reduction in bone marrow oedema, diminished periarticular effusion, and visible widening of joint space — suggesting the process reaches beyond surface-level symptom management.

Defect grade and size in the candidacy decision

The SUMMIT trial provides a useful reference point for understanding where the size threshold matters clinically. Patients with focal defects measuring 3 cm² or more showed superior KOOS pain and function scores with MACI compared with microfracture at both two and five years — evidence that the mid-to-large focal lesion is a distinct territory where marrow-stimulation alone tends to fall short. ChondroFiller injection's 6 cm² size ceiling places it in precisely that space.

Scan reports often list a defect area alongside the ICRS or Outerbridge grade. As a practical guide: defects below roughly 2 cm² are often addressable with established marrow-stimulation or autograft techniques; those between approximately 2 cm² and 6 cm², graded ICRS III or IV, are where ChondroFiller injection is most directly relevant. Above 6 cm², or where the lesion is structurally unstable and localised in a way that demands reconstruction from below, arthroscopic surgery is likely the more appropriate route.

Diffuse damage affecting multiple compartments — typically classified as Kellgren-Lawrence Grade III or IV osteoarthritis — falls outside this focal-defect profile. Management there follows a separate pathway, which may involve joint-preservation combinations or, in end-stage disease, joint replacement. The candidacy criteria discussed in this article apply to focal, bordered lesions rather than to widespread articular deterioration.

Why this is an outpatient injection, not a surgical procedure

For patients who have been told they need cartilage surgery — a two-stage procedure such as ACI or MACI, involving an operating theatre, general anaesthetic, and a rehabilitation period that typically includes an extended phase of restricted weight-bearing — the injectable pathway represents a meaningfully different route.

Because ChondroFiller injection is placed image-guided into a fluid joint environment, no surgical field preparation is required. This matters particularly for patients in whom general or spinal anaesthesia carries significant medical risk: those with cardiac or respiratory conditions, patients on anticoagulation therapy, or anyone whose overall health makes a theatre-based procedure inadvisable. For that group, an image-guided outpatient placement may open a candidacy window where surgical repair would be contraindicated or strongly discouraged.

Recovery also diverges from the surgical route. Cell-based procedures such as ACI commonly require strict non-weight-bearing for a considerable period post-implantation; the injectable pathway does not carry equivalent post-procedure restrictions, though individual guidance depends on the joint treated and the characteristics of the defect.

Precision of placement directly influences outcome. The scaffold must fill the defect fully and bond accurately to the surrounding cartilage margins; image-guided technique and clinical familiarity with the product shape what is achievable. The London Cartilage Clinic on Harley Street is the UK certified delivery centre for this treatment, with Professor Paul Y. F. Lee leading its application across multiple joints — a factor worth considering when evaluating where to be assessed.

What the outcome evidence shows

Published data for ChondroFiller injection — drawn from the manufacturer's Clinical Evaluation Report (Version 09, April 2025) and peer-reviewed series — centre on three measurable outcomes: functional scores, structural MRI findings, and safety.

In the knee, IKDC scores improve by approximately 30 points over 12 months. The IKDC has a recognised minimum clinically important difference of around 11–16 points, so a 30-point shift represents a substantial functional gain rather than a marginal one. Structural repair on MRI, assessed using the MOCART scoring system, reaches 70–87 across published studies — indicating consistent defect fill and tissue integration on imaging.

On safety, the reported complication rate is approximately 0% and the reoperation rate 3–8%. The CER's comparative table places those figures against microfracture, where reoperation rates reach up to 41%, and ACI/MACI, where complication rates may reach 17% and reoperation rates up to 37%.

Two caveats deserve equal weight. First, the comparison data originate from a manufacturer-sponsored evaluation, not an independent head-to-head randomised controlled trial against surgical repair in matched focal defects — such trials are not yet published, and the figures should be read in that context. Second, the IKDC and MOCART anchors apply to the focal defect candidacy profile described in earlier sections. Extended combination protocols — such as ChondroFiller injection combined with Arthrosamid or autologous cell therapy for advanced osteoarthritis — have not yet been validated as complete protocols in randomised trials, and the outcome data cannot be extended to those settings.

When ChondroFiller injection may not be suitable

Several clinical situations place a patient outside the focal defect profile that ChondroFiller injection is designed to address.

The standard exclusions applied across cartilage repair pathways — and confirmed at every clinical assessment — include active joint infection, inflammatory arthropathy such as rheumatoid arthritis, uncorrected mechanical malalignment, and known allergy to collagen. These are not restrictions unique to this treatment; they are universal filters for regenerative cartilage procedures, reviewed as part of any candidacy evaluation.

Very large or structurally unstable Grade III/IV defects may require an arthroscopic step — such as AMIC — rather than a purely injectable approach. The injection-only route addresses the isolated, stable focal lesion population; the most complex or unstable lesions may still warrant keyhole surgery as the more appropriate primary intervention.

Patient age and BMI thresholds specific to ChondroFiller injection are not defined in current published documentation; suitability in these respects is determined individually based on the full clinical picture at consultation.

A formal assessment — including imaging review — is the only reliable way to confirm whether the injectable scaffold route is appropriate. The London Cartilage Clinic on Harley Street offers that assessment; appointments can be arranged at londoncartilage.com. Ultimately, candidacy is determined by a clinician reviewing your imaging and history, not by a symptom checklist or defect size alone.